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Arianne C. van Bon4, Joop P. van den Bergh5, Marc JTM. Mol6, Cees J. Tack7 and Hans Knoop1Abstract
Background: Fatigue is frequently reported by patients with type 1 diabetes mellitus. A recent study showed
that 40 % of patients experienced severe fatigue that lasted for more than six months and was accompanied by
substantial impairments in daily functioning. Currently, there is no effective treatment available for chronic fatigue
in patients with type 1 diabetes. Cognitive behaviour therapy aimed at cognitions and behaviours that perpetuate
fatigue is effective in reducing fatigue in other chronic diseases. Recent research showed that these cognitions
and behaviours are also potential determinants of fatigue in type 1 diabetes. We designed Dia-Fit, a web-based
cognitive behaviour therapy for severe and chronic fatigue in patients with type 1 diabetes. This patient-tailored
intervention is aimed at reducing fatigue by changing cognitions and behaviours assumed to maintain fatigue.
The efficacy of Dia-Fit will be investigated in this study.
Methods/design: A randomised controlled trial will be conducted in 120 patients with type 1 diabetes who are
chronically and severely fatigued. Patients will be randomised to a treatment or waiting list group. The treatment
group will receive Dia-Fit, a blended care therapy consisting of up to eight internet modules and face-to-face
sessions with a therapist during a five-month period. The treatment will be tailored to the fatigue-maintaining
cognitions and behaviours that are relevant for the patient and are determined at baseline. The waiting list
group will receive Dia-Fit after a waiting period of five months. The primary outcome measure is fatigue severity.
Secondary outcome measures are functional impairment and glucose control determined by haemoglobin A1c
and blood glucose variability.
Discussion: To our knowledge, this is the first study investigating the efficacy of a cognitive behavioural
intervention for chronic fatigue in patients with type 1 diabetes.
Trial registration: Dutch trial register NTR4312 (10 December 2013).
Keywords: Chronic fatigue, Type 1 diabetes, Cognitive behaviour therapy, Blended-care, Internet, Study protocol,
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Diabetes mellitus is a highly prevalent health care prob-
lem: about 380 million adults are affected by diabetes
worldwide and the number is expected to rise to 590
million adults by the year 2035 [1]. About 10 % of
patients are diagnosed with type 1 diabetes mellitus
(T1DM). T1DM is an autoimmune disorder, mostly di-
agnosed in childhood or adolescence, leading to beta cell
destruction and an insulin secretion defect [2]. Patients
need to inject insulin to control their blood glucose
levels. T1DM is associated with medical complications
both acute and long term, such as cardiovascular dis-
eases, nephropathy, neuropathy and retinopathy [2]. The
goal of diabetes treatment is to control blood glucose
levels at a near normal level to delay or prevent medical
complications and increase the quality of life of patients.
Optimal diabetes control requires continuous diabetes
self-management.
The proposed study described in this paper will focus
on severely fatigued patients with T1DM. Fatigue is an
often-reported symptom by patients with T1DM. In a
cross-sectional study by our research group of 214 pa-
tients with T1DM, 40 % of patients suffered from severe
fatigue lasting at least for six months [3]. Chronic fatigue
was associated with more impairment in daily function-
ing, and fatigue was the most burdensome symptom of
all assessed diabetes-related symptoms. [3]. Other stud-
ies that have investigated fatigue in T1DM patients
provide limited information about the impact and
chronicity of fatigue [4, 5]. However, fatigue is also a
highly prevalent symptom in other chronic diseases. Fa-
tigue was found to be a burdensome and invalidating
symptom in patients with type 2 diabetes [6–8] and
highly prevalent in patients with rheumatoid arthritis
and neuromuscular disorders [9–11].
The etiology of severe fatigue in T1DM is not well under-
stood. It seems obvious that physiological diabetes-related
factors such as haemoglobin A1c (HbA1c) levels or varia-
tions in blood glucose levels are associated with fatigue.
While fatigue is a classical presenting symptom of hypergly-
caemia, in our cross-sectional study no relationship be-
tween glucose control (HbA1c levels) and fatigue severity
was found [3]. Also, parameters gathered during con-
tinuous glucose monitoring such as the blood glucose
variability were unrelated to persistent fatigue. Other
diabetes-related factors were correlated to fatigue: the
number of complications due to diabetes, diabetes-
related distress and diabetes specific self-efficacy. Also,
there was a univariate relationship between fatigue
and somatic comorbidity. In a multiple regression,
several cognitive behavioural factors were found to be
potential determinants of fatigue: disrupted sleep-
wake patterns, low physical activity, catastrophising
thoughts about fatigue and low self-efficacy with respect tofatigue and pain. These cognitive behavioural factors
are also known to be determinants of fatigue in other
chronic diseases [12–15]. Based on the available litera-
ture on diabetes and chronic fatigue in other chronic
illnesses, we designed a cognitive behavioural model
of fatigue in T1DM (Fig. 1). We assume that fatigue
in T1DM is initially triggered by hyperglycaemia and/
or diabetes-related factors such as the number of
complications due to diabetes and/or somatic comor-
bidities. Once the fatigue has been triggered, other
factors perpetuate it. We assume that these perpetuat-
ing factors are cognitive behavioural factors such as
1) a decreased or deregulated level of physical activity,
2) sleep disturbances and disrupted sleep-wake
rhythm and 3) dysfunctional cognitions with respect
to fatigue. Furthermore, we assume 4) pain and pain-
related cognitions and 5) a lack of social support and/
or negative social interactions to be perpetuating
factors of fatigue in T1DM. All the aforementioned
factors have been identified as determinants of fatigue
in patients with T1DM and/or have repeatedly been
found to be perpetuating factors of fatigue in other
chronic illnesses [3, 12–15]. Finally, 6) diabetes-
related distress is added to the model, because an as-
sociation between fatigue and diabetes-related distress
was found [3]. The six perpetuating factors can be
addressed in cognitive behaviour therapy (CBT) for
fatigue. Previous research has shown that CBT is ef-
fective in reducing fatigue in other chronic diseases
and conditions [16–18].
To our knowledge, there are no studies that tested the
efficacy of interventions specifically aimed at chronic fa-
tigue in patients with T1DM. We propose that CBT
aimed at the maintaining factors of fatigue will lead to a
reduction of fatigue and associated disabilities. For this
purpose, we developed Dia-Fit, a web-based cognitive
behavioural intervention aimed at reducing fatigue. Dia-
Fit is a blended-care therapy that consists of web-based
modules supported by face-to-face sessions with a ther-
apist. Blended care has the advantage of limiting the
therapist time needed to deliver the intervention and redu-
cing travel time, expenses and rigid appointments for pa-
tients. The primary objective of this study is to investigate
the efficacy of Dia-Fit for chronic fatigue in patients with
T1DM in a randomised controlled trial. The primary out-
come measure is fatigue severity. Secondary outcome mea-
sures are the level of disabilities, HbA1c and blood glucose
variability. We will also investigate the long-term effects of
Dia-Fit in a follow-up, six months after the intervention. If
Dia-Fit leads to the expected improvement in fatigue sever-
ity compared to the waiting list, we will perform a medi-
ation analysis to determine whether changes in the
proposed fatigue maintaining factors mediate the effect of
Dia-Fit on fatigue severity.
Fig. 1 Model of perpetuating factors of fatigue in patients with T1DM
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Study design
The study is a randomised controlled trial (RCT) and
will be conducted at the Expert Center for Chronic Fa-
tigue (ECCF) of the Radboud University Medical Center.
Patients who are eligible to participate will be randomly
allocated to either the intervention group or a waiting
list group. Patients allocated to the intervention group
will directly receive the Dia-Fit intervention, while pa-
tients allocated to the waiting list group will receive the
Dia-Fit intervention after a waiting period of five
months. Assessments are planned before and after the
intervention and the waiting list period. In both condi-
tions, patients will be assessed again at a follow-up six
months after receiving the treatment (Fig. 2).Fig. 2 Flowchart of the trial design. T0 = baseline assessment; T1 = second
waiting list, T3 = follow-up assessmentRecruitment process and study population
One hundred and twenty chronically fatigued patients
with T1DM will be included. Patients will be recruited
from the diabetes outpatient clinic of the Radboud Uni-
versity Medical Center and three general hospitals all lo-
cated in the South East Netherlands. Patients will also
be recruited through websites and social media. Patients
of the diabetic outpatient clinics will be screened by
their treating consultant for the sociodemographic and
medical criteria of eligibility (criteria 1, 2 and 3 of the in-
clusion criteria and criteria 1 through 7 of the exclusion
criteria). Inclusion criteria and exclusion criteria are
listed in Table 1.
Patients who are eligible will receive a letter from their
consultant with information about the possibility ofassessment; T2 = post-treatment assessment for patients on the
Table 1 Inclusion and exclusion criteria
Inclusion criteria
(1) Diagnosis of type 1 diabetes for at least 1 year
(2) Between 18 and 70 years old
(3) Able to read, speak and write Dutch
(4) Severely fatigued operationalised as scoring ≥ 35 on the subscale
fatigue severity of the CIS (Checklist Individual Strength)
(5) Fatigued for at least 6 months
Exclusion criteria
(1) Moderate to severe renal failure operationalised as having a
glomerular filtration rate (GFR) ≤ 45
(2) Blindness or severe visual impairment
(3) Medical history of congestive heart failure
(4) Medical history of a stroke in the past five years
(5) Body mass index (BMI) ≥ 40
(6) Wheelchair-dependent
(7) Other concurrent psychiatric or medical comorbidity that
could explain the fatigue
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of this research project. Attached to the letter, patients
will receive a short screening questionnaire consisting of
the Checklist Individual Strength (CIS) [19] and a ques-
tion about the duration of the fatigue (criteria 4 and 5 of
the inclusion criteria). Patients who are interested in
participating can fill in the questionnaire and send it
back, together with a written consent giving permission
to the researcher (JM) to contact them. Patients who
have a score of 35 or higher on the subscale fatigue se-
verity of the CIS and who indicate that they are fatigued
for six months or longer will receive further information
about the study, both by telephone and in writing. Pa-
tients can decide to participate in the study within a
period of two weeks from the time that the researcher
contacted them. If patients are willing to participate,
they will be asked to give written informed consent for
participation in the study. They will then be invited for a
baseline assessment at the ECCF. During baseline assess-
ment, patients fill in the Beck Depression Inventory
(BDI) [20] and the Symptom Check List (SCL90) [21].
Patients with a score of 4 or higher on the BDI and/or a
total score of 164 or higher on the SCL90, which is
higher than the mean and two standard deviations of
healthy people from the general population [21], will be
screened for the presence of a psychiatric disorder
using the Mini-International Neuropsychiatric Interview
(M.I.N.I.) [22]. Patients will be excluded if they meet the
criteria of the M.I.N.I. for: depressive episode, suicidality,
(hypo-)manic episode, panic disorder, obsessive-compulsive
disorder, post-traumatic stress disorder, alcohol dependence
and alcohol abuse, substance dependence and substanceabuse, psychotic disorders, anorexia nervosa, bulimia ner-
vosa and/or generalised anxiety disorder.
Patients who contact the researcher in response to in-
formation about the study in the media and are not
treated in one of the four participating hospitals will first
be screened for eligibility by a consultant of the diabetes
outpatient clinic of the Radboud University Medical
Center.
Ethical approval
This study has been reviewed and approved by the Medical
Ethical Committee of the Radboud University Medical
Center (registration number 2013/165, NL43178.091.13).
The study has also been approved and registered by the
local ethical committees of the involved general hospitals:
Rijnstate Ziekenhuis, Canisius-Wilhelmina Ziekenhuis and
VieCuri Medisch Centrum. The study has been registered
in the DutchTrial Register (trial number NTR4312). All pa-
tients will receive verbal and written information about the
study, and all patients must give written informed consent
before randomisation and inclusion.
Intervention
Dia-Fit consists of blended care, a combination of as-
signments, information and e-mail contact delivered via
an internet portal and individual face-to-face sessions
with a therapist. The total duration of the intervention is
five months. During these months patients get online
information and assignments, have fortnightly e-mail
contact with their therapist and receive five to eight
face-to-face sessions. The intervention is aimed at chan-
ging cognitions and behaviours thought to maintain fa-
tigue; these are depicted in Fig. 1. Which cognitions and
behaviours are relevant and applicable for the individual
patient will be determined on the basis of cut-off scores
on various questionnaires filled in at baseline assessment
and the clinical interview by the therapist. For each
fatigue-perpetuating factor a treatment module is devel-
oped. In this way the intervention can be tailored based
on the applicable factors. Patients can follow from three
up to eight of the following modules:
1. Goals setting. All patients receive this module. The
module is the start of the Dia-Fit intervention and
consists of psycho-education about fatigue in T1DM
and the cognitive behavioural model of fatigue in
T1DM. There will be a discussion about which mod-
ules are relevant for the patient. The patient will for-
mulate goals of the therapy that, if attained, imply
that a patient is no longer severely fatigued and no
longer limited by fatigue in daily functioning.
2. Regulation of the sleep-wake pattern. At baseline,
patients register bedtimes, times that they get up
and the time slept during the day for two
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patients score 60 or higher on the subscale sleep of
the Sickness Impact Profile 8 (SIP8) [23] and/or if
their bedtime and get-up time registration shows
evidence of a disrupted sleep-wake pattern. In this
module the importance of a regular sleep-wake cycle
is discussed. Patients are asked to maintain fixed
bedtimes and get-up times and to stop sleeping or
lying down during the day.
3. Formulating helpful fatigue-related beliefs. This
module addresses low self-efficacy with respect to
fatigue, fatigue catastrophising and the tendency of
patients to focus on fatigue. Dysfunctional beliefs
will be reformulated and patients will practice
applying helpful beliefs in their daily life. If patients
score 19 or lower on the Self Efficacy Scale (SES) for
fatigue [24] and/or 16 or higher on the Fatigue
Catastrophising Scale (FCS) [25], they will receive
this module. The tendency to focus on fatigue will
be addressed if patients score 30 or higher on the
Illness Management Questionnaire (IMQ) subscale
focusing on symptoms [26]. Patients will learn how
to shift their attention to other things instead of
fatigue, such as activities or the environment. Patients
will also be asked to stop talking about fatigue and to
ask significant others to stop talking about fatigue.
4. Activity regulation and increasing the level of
activity. This module is applicable for all patients
and focuses on gradually increasing activity. The
physical activity pattern of patients will be assessed
with an actometer at baseline. An actometer is a
small device which is worn at the ankle during two
consecutive weeks [27]. On the basis of the scores of
the actometer, each patient will be categorised in
one of the two activity patterns: relatively active or
low active. The physical activity of relatively active
patients varies from day to day and is often
characterised by ‘all or nothing’ behaviour.
Relatively active patients first learn to divide their
activities more evenly across the day and week and
then increase their physical activity with a graded
activity program. Patients can choose to increase
their physical activity level either by walking or
biking. They start walking or biking at least two
times a day and increase their walking or biking
time step by step. Patients with a low active
pattern immediately start by increasing their
physical activity. After patients have increased
their physical activity, they apply the same
principles to social or mental activities. Only
patients who experience specific problems with
social or mental activities will receive these
elements of the module. Patients who do not need
this specific step and believe that they are able toincrease their level of activity will proceed with
other modules and the realisation of their goals.
5. Coping with pain. This module focuses on
dysfunctional cognitions regarding pain. It is
assumed that catastrophising thoughts with respect
to pain will make it difficult for patients to increase
their activity level. Therefore, patients learn to use
more helpful beliefs with respect to pain. Patients
who score 55 or lower on the pain subscale of the
SF36 [28] and/or 16 or higher on one of the two
subscales, magnification and rumination, of the
Pain Catastrophising Scale (PCS) [29] will receive
this module.
6. Optimalisation of social support and interactions.
T1DM patients with severe fatigue can experience
problems in their interactions with significant others
due to a lack of understanding or support. In this
module patients learn how to improve their
communication with significant others about fatigue.
In exercises they learn how to communicate with
others about fatigue and how to be more assertive.
There is also an emphasis on having more realistic
expectations with respect to the reaction of others.
This module is indicated if patients score 50 or
higher on the subscale discrepancy and/or score 14
or higher on the subscale negative interactions of
the Sonderen Social Support Inventory (SSI) [30].
7. Reducing diabetes-related distress. T1DM is a
chronic disease, and its management is demanding
for patients. Patients can develop diabetes-related
distress, for example, related to the fear of the devel-
opment of medical complications, hypoglycaemia or
deregulated blood glucose values. In this module pa-
tients concretise the elements of diabetes that they
find stressful and learn how to better cope with
these elements. The module is indicated if patients
score 30 or higher on the Problem Areas in Diabetes
(PAID) questionnaire [31].
8. Step-by-step realisation of goals. All patients end
Dia-Fit with the realisation of goals. Patients realise
the preset goals and evaluate the treatment effects.
Patients who work less because of their fatigue will
resume work in this module. Therapists will discuss
with patients how to prevent relapse.
Development of Dia-Fit and usability testing
The information and assignments provided on the Dia-
Fit portal are developed by experts on chronic fatigue
and type 1 diabetes. Usability testing was used to test
the portal. Three patients with T1DM, recruited
from the diabetes outpatient clinic of the Radboud
University Medical Center, participated in the usability
tests. They were interviewed about the usability of the
portal and completed various tasks on the website in the
Menting et al. Trials  (2015) 16:262 Page 6 of 9presence of a researcher using the ‘think aloud’ technique.
The intervention was improved on the basis of the find-
ings of the usability test.
Training, supervision and treatment integrity
All therapists are experienced cognitive behaviour thera-
pists working at the ECCF. Therapists will be trained in
delivering Dia-Fit. They will receive bi-weekly supervi-
sion from an experienced clinical psychologist (HK).
Treatment integrity will be determined by digitally re-
cording all face-to-face sessions and saving all e-mail
contacts of Dia-Fit. At the end of the study, 5 % of the
sessions and the e-mail contacts will be randomly se-
lected and evaluated to assess to what extent the Dia-Fit
treatment was delivered according to protocol.
Outcome measures
The primary outcome measure is fatigue severity mea-
sured with the fatigue severity subscale of the CIS [19].
The CIS subscale fatigue consists of eight items that are
scored on a 7-point Likert scale from (1) ‘Yes, that is
true’ to (7) ‘No, that is not true’. Scores range from 8 to
56 with higher scores indicating more severe fatigue. Se-
vere fatigue is operationalised as scoring 35 and higher,
which is higher than the mean plus two standard devia-
tions of a healthy control group [32]. The CIS is a valid
and reliable instrument that has been used before in pa-
tient groups with chronic diseases [12, 13].
Secondary outcome measures are limitations in daily
functioning and diabetes control. Limitations in daily
functioning will be measured with the total score on the
Sickness Impact Profile 8 (SIP8) [23]. The SIP8 measures
functional disability in eight different domains of func-
tioning: sleep and rest, homemaking, mobility, social
interactions, ambulation, leisure activities, alertness be-
haviour and work limitations. The eight subscale scores
are added to provide one weighted score of disability
(SIP8 total score). Higher scores indicate more disabilities.
Diabetes control will be determined with two diabetes-
specific clinical measurements: HbA1c values and blood
glucose variability. HbA1c values are routinely assessed at
the diabetes outpatient clinics every three months. When-
ever possible, assessment of HbA1c for the study and the
routine assessment will be combined. Blood glucose vari-
ability will be derived from 7-point blood glucose profiles,
measured for two consecutive days. The standard deviation
of the mean glucose level is used as an indicator of blood
glucose variability [33].
Questionnaires that will help decide which modules of
the Dia-Fit intervention should be used are described in
the section Intervention. Based on the model of fatigue
in T1DM several fatigue- and diabetes-related cognitions
and behaviours are assessed. Questionnaires and meas-
urement points are listed in Table 2.Assessments
The baseline assessment (T0) consists of two appoint-
ments at the ECCF. During both test sessions patients
will complete questionnaires (Table 2). In the two weeks
between the two sessions patients will wear an act-
ometer to measure physical activity [27]. Patients will
also record their symptoms and activities in a diary. In
addition, blood glucose variability and HbA1c will be
assessed. After the baseline assessment patients will be
randomised to either the Dia-Fit intervention group or
the waiting list group. After five months the second as-
sessment will be done (T1), consisting of the same mea-
sures as at baseline assessment. After T1 the waiting list
group will start with Dia-Fit. The waiting list group will
receive an extra assessment after therapy (T2). All pa-
tients will be assessed six months after finishing Dia-Fit
(T3). T2 and T3 will consist of a limited number of mea-
sures (Table 2).
Adverse events
Adverse events (AEs) will be assessed at T1. Patients will
be asked to fill in a questionnaire regarding the develop-
ment of new symptoms during the therapy or waiting
period. All AEs that are spontaneously reported by pa-
tients or observed by the investigator will be recorded
and reported to the ethical committee. The investigator
will also record and report serious adverse events (SAEs)
to the ethical committee. Previous research has shown
that CBT for fatigue is a safe treatment [34].
Treatment adherence
Treatment adherence will be determined in two ways.
First, therapists will be asked to rate the degree of adher-
ence to the Dia-Fit intervention by the patient on a scale
of 0 to 10 at the end of the therapy. Second, patients will
be asked to rate the degree to which they adhered to the
different modules of the Dia-Fit treatment at the end of
the therapy. Both scores will be correlated with the
change score (pre-treatment versus post-treatment) on
the primary outcome measure.
Sample size
Sample size calculation was based on the guidelines of
Borm and colleagues (2007) [35] and Van Breukelen
(2006) [36] for analysis of covariance (ANCOVA) in ran-
domised controlled trials. On the primary outcome par-
ameter, the CIS fatigue severity, we assumed a clinically
relevant difference in post-treatment scores of 6 between
the Dia-Fit and the waiting list condition [37]. With a
power of 0.90, a two-sided alpha of 0.05 and a standard
deviation of 8.6, a minimum number of 45 patients
would be needed per condition when using a t-test. Ac-
cording to Borm and colleagues (2007) this number of
patients can be multiplied by a ‘design factor’ when
Table 2 Time points of all measures
Measurements T0 T1 T2 T3
Main outcome measures
Fatigue severity Checklist Individual Strength (CIS, subscale fatigue) [19] X X X X
Secondary outcome measures
Limitations in daily functioning Sickness Impact Profile 8 (SIP8, total score) [23] X X X X
Diabetes regulation HbA1c; blood glucose variability [33] X X X X
Indicators for modules
Sleep problems Sickness Impact Profile 8 (SIP8, subscale sleep) [23] X X
Dysfunctional cognitions with respect to fatigue Self Efficacy Scale (SES) [24] X X
Fatigue Catastrophising Scale (FCS) [25] X X
Illness Management Questionnaire (IMQ) [26] X X
Level of physical activity Actometer [27] X X
Pain severity and impact of pain SF36 Questionnaire (subscale pain) [28] X X
Pain Catastrophising Scale (PCS) [29] X X
Cognitions with respect to social support and social
interactions
Sonderen Social Support Inventory (SSI) [30] X X
Diabetes-related distress Problem Areas in Diabetes (PAID) [31] X X
Other measures
Depression Beck Depression Inventory (BDI) [20] X X
Psychological distress SCL90 [21] X
Cognitions regarding fatigue Fatigue Quality List (FQL) [39] X X
Cognitions with respect to activity Tampa Scale for Kinesiophobia 2 (TSK2) [40] X X
Affective quality of pain McGill Pain Questionnaire (MPQ) [41] X X
Causal attributions CAL diabetes [42] X X
Diabetes quality of life Diabetes Quality of Life Brief Clinical Inventory (DQOL_BCI) [43] X X
Cognitions regarding symptoms of chronic illness Illness Cognition Questionnaire (ICQ) [44] X X
Cognitive and Behavioural Responses to Symptoms Questionnaire
(CBRSQ) [45]
X X
Self-efficacy regarding diabetes self-care Confidence in Diabetes Self-Care Scale (CIDS) [46] X X
Physical activity International Physical Activity Questionnaire (IPAQ) [47] X X
T0 = baseline assessment; T1 = second assessment; T2 = post-treatment assessment for patients on the waiting list, T3 = follow-up assessment
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correlation coefficient between baseline and second as-
sessment of fatigue severity. As we have no data on
which to base this correction, we used a conservative es-
timate of 1 as a factor which corresponds to a relatively
low correlation between baseline and second assessment
of about r = .20 (1 - .202 = .96 ≈ 1). Assuming a drop-
out rate of 25 %, 60 patients per condition need to be
randomised (n = 120 in total).
Randomisation
Patients will be randomised in an equal ratio (1:1) to
one of the two groups: 1) intervention group or 2) wait-
ing list group. A computer randomisation program that
is created by an independent statistical expert will be
used for randomisation. Block randomisation is used
with blocks of 6. Patients will be stratified into twogroups: 1) patients recruited from hospitals and 2) pa-
tients recruited via media. A test assistant who is not in-
volved in the study will do the random allocation in the
presence of the patient after the baseline assessment.
The researcher (JM) will also be present to plan appoint-
ments with the therapist and for the second assessment.
The researcher is not blinded for treatment allocation. A
researcher blinded for treatment allocation will do the
statistical analysis.
Statistical analysis
To test if there is a difference between the intervention
group and the waiting list conditions on the primary
outcome measure at second assessment (T1), ANCOVA
will be used with the score on the second assessment as
the dependent variable, the baseline score on the
dependent measure as covariate, and condition as fixed
Menting et al. Trials  (2015) 16:262 Page 8 of 9factor [36]. Analysis of the data will be based on
intention to treat. Missing values will be replaced with
multiple imputation with fully conditional specification
with at least five imputations. When statistically signifi-
cant differences are found, a sensitivity analysis will be
performed on the basis of different assumptions about
the values of missing data. For the secondary outcome
measures, limitations of daily functioning and diabetes
control, the same analyses will be used. To determine if
the expected positive result of CBT will be sustained at
follow-up, scores at follow-up (T3) of patients treated
with CBT directly or after the waiting period will be
compared with the scores at post-treatment (T1 or T2)
using paired t-tests.
Finally, we will test with multiple mediation which
changes in the proposed fatigue maintaining cognitions
and behaviours mediate the expected effect of the inter-
vention on the primary outcome parameter of fatigue se-
verity. The proposed mediators are factors that are
thought to maintain fatigue severity. The mediation ana-
lysis will be conducted according to the approach of
Preacher and Hayes [38]. Significance of the mediation
effects will be determined using a non-parametric boot-
strap approach which increases the power to detect sig-
nificant effects even in small, non-normally distributed
samples [38].Discussion
To our knowledge, this study is the first randomised
controlled trial testing the efficacy of a web-based cogni-
tive behavioural intervention for chronic fatigue in pa-
tients with T1DM. Chronic fatigue is highly prevalent in
T1DM and is experienced by patients as one of the most
disabling symptoms of the illness. An effective treatment
focusing on fatigue in patients with T1D is not yet
available.
The blended-care character of Dia-Fit, consisting of
web-based information, assignments and e-mail contact
supported by face-to-face sessions, is a promising ap-
proach for both patients and therapists. The tailored ap-
proach of Dia-Fit makes it possible to concentrate on
fatigue maintaining factors that are relevant for each in-
dividual patient.
In conclusion, the results of the described study will
provide information about the efficacy of CBT for severe
fatigue in patients with T1DM and, one hopes, will con-
tribute to the treatment of fatigue in T1DM.Trial status
Recruitment of the Dia-Fit study is ongoing. The recruit-
ment started in January 2014 and is expected to end in
February 2016.Abbreviations
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